|
Match
|
Document |
Document Title |
|
|
US20100008918 |
Methods for dosing an actriib antagonist and monitoring of treated patients
In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain... |
|
|
US20170114147 |
Antibodies Against Tissue Factor Pathway Inhibitor
The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of... |
|
|
US20170080070 |
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The... |
|
|
US20170073427 |
ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF
The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For... |
|
|
US20160319006 |
ANTIBODIES SPECIFIC FOR THE PROTOFIBRIL FORM OF BETA-AMYLOID PROTEIN
Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human β-amyloid peptide as compare to low molecular... |
|
|
US20160279215 |
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The... |
|
|
US20160200805 |
Complement Pathway Inhibitors Binding To C5 And C5a Without Preventing The Formation Of C5b
The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an... |
|
|
US20160185842 |
14-3-3 Antagonists for the Prevention and Treatment of Arthritis
The invention provides compositions and methods for treating arthritis. |
|
|
US20160159923 |
ANTIBODIES TO MATRIX METALLOPROTEINASE 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9... |
|
|
US20160159891 |
MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF
The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other... |
|
|
US20160159890 |
METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND HUNTINGTON'S DISEASE
This invention relates generally to methods of treatment for neurodegenerative diseases such as Alzheimer's disease, Alzheimer's-related diseases, and Huntington's disease, and more specifically... |
|
|
US20160137735 |
METHOD OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES
Compositions and methods for treating MM are provided herein. |
|
|
US20160108116 |
VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS
Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of... |
|
|
US20160046726 |
SPECIFIC BINDING PROTEINS AND USES THEREOF
The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR... |
|
|
US20160024214 |
Antibodies Against Human NKG2D and Uses Thereof
The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the... |
|
|
US20160024198 |
CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention... |
|
|
US20150344576 |
HUMAN ANTI-KIR ANTIBODIES
Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a... |
|
|
US20150307609 |
OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as... |
|
|
US20150259406 |
Pharmaceutical Composition of an Antigenic Tau Peptide Reconstituted in a Liposome and Related Antibodies and Cell Lines
The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with... |
|
|
US20150239985 |
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject... |
|
|
US20150239980 |
ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin α-4... |
|
|
US20150232542 |
HUMAN ANTI-ALPHA-SYNUCLEIN ANTIBODIES
Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to... |
|
|
US20150231235 |
COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent. |
|
|
US20150197568 |
Compounds
Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating... |
|
|
US20150140002 |
USE OF A PCSK9 INHIBITOR TO TREAT HYPERLIPIDEMIA
The present invention provides methods for treating hyperlipidemia in patients who are not on statin therapy. The methods of the present invention comprise administering to a patient a... |
|
|
US20150132309 |
KLOTHO BETA
The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. |
|
|
US20150093381 |
FIXED DOSING OF HER ANTIBODIES
The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab. |
|
|
US20150093375 |
METHODS FOR INHIBITING OCULAR ANGIOGENESIS
The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders. |
|
|
US20150010568 |
COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFICALLY ANTAGONIZING GDF8 AND OR ACTIVIN A
The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific... |
|
|
US20140356355 |
IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and... |
|
|
US20140322201 |
METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES
Compositions and methods for treating MM are provided herein. |
|
|
US20140286958 |
Interleukin-31 Monoclonal Antibody
An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary... |
|
|
US20140286953 |
HEPCIDIN, HEPCIDIN ANTAGONISTS AND METHODS OF USE
The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related... |
|
|
US20140255412 |
Pharmaceutical Composition of an Antigenic Tau Peptide Reconstituted in a Liposome and Related Antibodies and Cell Lines
The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with... |
|
|
US20140220027 |
1D05 PCSK9 ANTAGONISTS
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present... |
|
|
US20140205598 |
Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating... |
|
|
US20140199315 |
Sp35 Antibodies and Uses Thereof
Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35... |
|
|
US20140161798 |
ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS
The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9. |
|
|
US20140154243 |
SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR
Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent... |
|
|
US20140134103 |
TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a... |
|
|
US20140120102 |
THERAPEUTIC AND DIAGNOSTIC METHODS RELATED TO LYSYL OXIDASE-LIKE 2 (LOXL2)
Provided are therapeutic, diagnostic, and prognostic methods for disease, including diseases associated with fibrosis and cancer using agents that bind to, inhibit, and/or detect lysyl... |
|
|
US20140079707 |
LOX AND LOXL2 INHIBITORS AND USES THEREOF
The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized... |
|
|
US20140010799 |
HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR
The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules,... |
|
|
US20130344073 |
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder... |
|
|
US20130330347 |
COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION
Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders. |
|
|
US20130309223 |
CD33 Antibodies And Use Of Same To Treat Cancer
The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33. |
|
|
US20130251703 |
ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) DIRECTED TO DOMAIN III AND DOMAIN IV OF HER3
The present invention relates to antibodies or fragments thereof that bind to a non-linear epitope within domain 3 of the HER3 receptor and inhibit both ligand-dependent and ligand-independent... |
|
|
US20130177569 |
NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 202P5A5 USEFUL IN TREATMENT AND DETECTION OF CANCER
A novel gene 202P5A5 and its encoded protein, and variants thereof, are described wherein 202P5A5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the... |
|
|
US20130171157 |
NOGO Receptor-Mediated Blockade of Axonal Growth
Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR... |
|
|
US20130129740 |
NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B
The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding... |